Biotechnology News and Research RSS Feed - Biotechnology News and Research

Cold 'sensor' hold key to new therapeutic target for treatment of frostbite and hypothermia

Cold 'sensor' hold key to new therapeutic target for treatment of frostbite and hypothermia

A cold 'sensor' which triggers the skin's vascular response to the cold could represent an exciting new therapeutic target for the treatment of frostbite and hypothermia, according to scientists at King's College London. [More]
GI Partners completes acquisition of 9911 Belward Campus Drive

GI Partners completes acquisition of 9911 Belward Campus Drive

GI Partners today announced that it has completed the acquisition of 9911 Belward Campus Drive located in Rockville, Maryland. The acquisition was made through TechCore, LLC, which is a $1 billion discretionary core real estate fund managed by GI Partners. [More]
FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active. [More]
AMSBIO announces DNA-In™ Neuro Transfection Reagent

AMSBIO announces DNA-In™ Neuro Transfection Reagent

AMSBIO announces DNA-In™ Neuro- a new generation transfection reagent developed specifically for maximum nucleic acid delivery into neurons, typically achieving a 2-fold or greater improvement in efficiency over currently available competing reagents. [More]
Scientists identify brain mechanism that drives our appetite for glucose-rich foods

Scientists identify brain mechanism that drives our appetite for glucose-rich foods

Scientists have discovered a mechanism in the brain that may drive our appetite for foods rich in glucose and could lead to improved treatments for obesity. [More]
Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex, Inc. today announced the successful completion of a multicenter Phase 1, multiple ascending dose clinical trial of VX15/2503 anti-Semaphorin 4D (SEMA4D) antibody in 42 adult patients with advanced, refractory solid tumors. [More]
Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. [More]
Researchers test new nanopore DNA sequencing technology to detect cause of antibiotic resistance

Researchers test new nanopore DNA sequencing technology to detect cause of antibiotic resistance

New nanopore DNA sequencing technology on a device the size of a USB stick could be used to diagnose infection - according to new research from the University of East Anglia and Public Health England. [More]
Study: Injectable 3D vaccines could help prevent cancer, infectious disease

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. [More]
Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Rutgers researcher receives NIH grant to develop rapid test to diagnose Ebola

Rutgers researcher receives NIH grant to develop rapid test to diagnose Ebola

Rutgers researcher David Alland, working with the California biotechnology company Cepheid, has received a grant of nearly $640,000 from the National Institutes of Health to develop a rapid test to diagnose Ebola as well as other viruses that can cause symptoms similar to Ebola. [More]
Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. [More]
Researchers discuss effects of mother-infant bedsharing

Researchers discuss effects of mother-infant bedsharing

Recommendations by physician groups to avoid bedsharing among mothers and their babies are intended to reduce sleep-related infant deaths. But evidence suggests that the risks of bedsharing have been over-emphasized, advice never to bedshare is unrealistic, and avoiding bedsharing may interfere with breastfeeding, according to an article in Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine published by Mary Ann Liebert, Inc., publishers. [More]
iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]
Genetics may play major role in Lou Gehrig's disease, study reveals

Genetics may play major role in Lou Gehrig's disease, study reveals

Genetics may play a larger role in causing Lou Gehrig's disease than previously believed, potentially accounting for more than one-third of all cases, according to one of the most comprehensive genetic studies to date of patients who suffer from the condition also known as amyotrophic lateral sclerosis, or ALS. [More]
Researchers suggest new strategy to control cellular identity and fate

Researchers suggest new strategy to control cellular identity and fate

A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities. [More]
Cellular Research announces commercial availability of Precise targeted RNASeq assays

Cellular Research announces commercial availability of Precise targeted RNASeq assays

Cellular Research today announced the commercial launch of its Precise targeted RNASeq assays. The company also announced the commercial availability of application-focused panels for the Precise assays, including panels designed for oncology, induced pluripotent stem cells and immunology. [More]
Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc., has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide. [More]
Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Breakthrough research could lead to prosthetic retinas for people suffering from retinal damage

Scientists have developed a new light-sensitive film that could one day form the basis of a prosthetic retina to help people suffering from retinal damage or degeneration. Hebrew University of Jerusalem researchers collaborated with colleagues from Tel Aviv University and Newcastle University in the research, which was published in the journal Nano Letters. [More]